GeneLink BioSciences, Inc. Hires National Sales Executive to Roll Out GeneLink's DNA Banking Product & Collection System.
November 2, 2000

MARGATE, N.J. November 2, 2000-GeneLink,Inc. (OTC BB:GNLK-news), GeneLink BioSciences, Inc., The World's First Family Centered DNA Bank and Hereditary Genetic Information Service, today announced that it has entered into an agreement with Ronald P. Robertson to act as Director of GeneLink's special markets, focusing on rolling out GeneLink's product to the cemetery and cremation markets.

Mr. Robertson has more than 30 years of experience as a Sales & Marketing Executive. Most recently, Mr. Robertson acted as Vice-President of Sales for The Loewen Group International, Inc., and was responsible for sales expense and revenue budgets for 1600 cemetery and funeral home locations. Mr. Robertson assisted The Loewen Group in growing its sales organizations from 485 to 4300 salespeople in four years. 

"I am very excited to be involved with GeneLink at this time of the genetic explosion. GeneLink's patent-pending, 'swabs only' product gives the Company a leg-up in the cemetery and cremation markets. There is currently a network in place consisting of thousands of trained salespeople in these industries that can put this product in the hands of the public", says Mr. Robertson. "Furthermore, the guarantee of long term storage of DNA up to 75 years at the University of North Texas Health Science Center at Fort Worth, a 105year old medical facility, will enable the Company to service these industries worldwide."

John R. DePhillipo, Chairman of GeneLink BioSciences, Inc. adds, "GeneLink is very proud to have such a qualified and respected member of the funeral and cemetery industry join our team to roll out our DNA Collection & Banking Services to these exclusive funeral industry markets. We are extremely excited, and anticipate wonderful success through the services of Mr. Robertson".

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE: GeneLink BioSciences, Inc.